Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-n-methyl-d-aspartate receptor antibody encephalitis: A retrospective review

2015 ◽  
Vol 30 (4) ◽  
pp. 212-216 ◽  
Author(s):  
Allen D. DeSena ◽  
Daniel K. Noland ◽  
Karen Matevosyan ◽  
Kathryn King ◽  
Lauren Phillips ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Retrospective Review ◽  
Therapeutic Plasma Exchange ◽  
Intravenous Methylprednisolone ◽  
Receptor Antibody ◽  
Aspartate Receptor

Adjunct therapeutic plasma exchange for anti-N-methyl-D-aspartate receptor antibody encephalitis: A case report and review of literature

2011 ◽  
Vol 26 (6) ◽  
pp. 362-365 ◽  
Author(s):  
M. Kamran Mirza ◽  
Jennifer Pogoriler ◽  
Kristen Paral ◽  
Vijayalakshmi Ananthanarayanan ◽  
Saptarshi Mandal ◽  
...  
Keyword(s):  
Case Report ◽  
Plasma Exchange ◽  
Therapeutic Plasma Exchange ◽  
Review Of Literature ◽  
Receptor Antibody ◽  
Aspartate Receptor

What is the evidence to support the use of plasma exchange as first-line therapy for N -methyl d -aspartate receptor antibody encephalitis?

2017 ◽  
Vol 33 (1) ◽  
pp. 126-127
Author(s):  
Eric A. Gehrie ◽  
Emily A. Coberly ◽  
Angela Treml ◽  
Christopher Tormey ◽  
Garrett S. Booth
Keyword(s):  
Plasma Exchange ◽  
First Line ◽  
Receptor Antibody ◽  
First Line Therapy ◽  
Aspartate Receptor ◽  
Line Therapy

scholarly journals Role of Therapeutic Plasma Exchange in Treatment of Tumefactive Multiple Sclerosis-Associated Low CD4 and CD8 Levels

2016 ◽  
Vol 8 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Kristen Lew ◽  
Nishith Mewada ◽  
Sahana Ramanujam ◽  
Bahareh Hassanzadeh ◽  
John E. Donahue ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Plasma Exchange ◽  
Demyelinating Disease ◽  
Therapeutic Plasma Exchange ◽  
Healthy Male ◽  
Intravenous Methylprednisolone ◽  
Initiation Of Therapy ◽  
Tumefactive Multiple Sclerosis

We report a 35-year-old healthy male who developed central nervous system inflammatory demyelinating disease consistent with tumefactive multiple sclerosis. About 2 weeks after onset of symptoms and prior to initiation of therapy, the patient had lymphopenia and low CD4 and CD8 levels. His lymphocyte count was 400 cells/µl (850–3,900 cells/µl), CD4 was 193 cells/µl (490–1,740 cells/µl) and CD8 was 103 cells/µl (180–1,170 cells/µl). He was treated with intravenous methylprednisolone followed by therapeutic plasma exchange, the levels of CD4 and CD8 normalized, and ultimately, he recovered completely.

Therapeutic plasma exchange in anti-N-methyl-D-aspartate-receptor (anti-NMDA-R) encephalitis associated with benign ovarian teratoma

2012 ◽  
Vol 27 (4) ◽  
pp. 227-228 ◽  
Author(s):  
Rashmi Batra ◽  
Yinghua Pang ◽  
Mark T. Friedman
Keyword(s):  
Plasma Exchange ◽  
Therapeutic Plasma Exchange ◽  
Ovarian Teratoma ◽  
Aspartate Receptor

Therapeutic Plasma Exchange Application in Children Requires Individual Decision

2020 ◽  
Author(s):  
Gürkan Atay ◽  
Demet Demirkol
Keyword(s):  
Plasma Exchange ◽  
Vascular Access ◽  
Pediatric Patients ◽  
Demyelinating Disease ◽  
Pediatric Intensive Care ◽  
Therapeutic Plasma Exchange ◽  
Transplantation Rejection ◽  
Access Problems ◽  
Uremic Syndrome

AbstractTherapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n = 11), renal transplantation rejection (15.4%, n = 6), liver failure (15.4%, n = 6), Guillain–Barre's syndrome (15%, n = 6), hemolytic uremic syndrome (7.7%, n = 3), acute demyelinating disease (7.7%, n = 3), septic shock (5.1%, n = 2), and intoxication (5.1%, n = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible.

Therapeutic plasma exchange in intensive care and intensive nephrology

2018 ◽  
Vol 20 (4) ◽  
pp. 394-403
Author(s):  
M. S. Vetsheva ◽  
◽  
K.E Loss . ◽  
O.L. Podkorytova ◽  
E.V. Lebedkov ◽  
...  
Keyword(s):  
Intensive Care ◽  
Plasma Exchange ◽  
Therapeutic Plasma Exchange

Therapeutic plasma exchange in a single center: Ibni Sina experience

2004 ◽  
Vol 30 (3) ◽  
pp. 181-184 ◽  
Author(s):  
Önder Arslan ◽  
Mutlu Arat ◽  
Ibrahim Tek ◽  
Erol Ayyildiz ◽  
Osman Ilhan
Keyword(s):  
Plasma Exchange ◽  
Therapeutic Plasma Exchange ◽  
Single Center

scholarly journals Pediatric Therapeutic Plasma Exchange: Coming of Age?

2021 ◽  
Author(s):  
Saptarshi Mandal ◽  
Aditi Sinha
Keyword(s):  
Plasma Exchange ◽  
Coming Of Age ◽  
Therapeutic Plasma Exchange
Sign in / Sign up

Export Citation Format

Share Document